UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 19, 2015
Bacterin International Holdings, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
| ||
| Delaware | ||
|
(State or Other Jurisdiction of Incorporation)
| ||
| 001-34951 | 20-5313323 | |
| (Commission File Number) |
(IRS Employer Identification No.)
| |
|
600 Cruiser Lane Belgrade, Montana |
59714 | |
| (Address of Principal Executive Offices) |
(Zip Code)
| |
| (406) 388-0480 | ||
|
(Registrant’s Telephone Number, Including Area Code)
| ||
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| ||
Item 7.01 Regulation FD Disclosure.
The Company has issued a press release entitled “Bacterin Announces signing of agreement with Yankee Alliance” which is attached as Exhibit 99.1 and incorporated herein.
The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No | Description | |
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated June 19, 2015 entitled “Bacterin Announces signing of agreement with Yankee Alliance” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 19, 2015 | BACTERIN INTERNATIONAL HOLDINGS, INC. | ||
| By: | /s/ Daniel Goldberger | ||
Name: Daniel Goldberger Title: Chief Executive Officer | |||
EXHIBIT INDEX
| 99.1 | Press Release of Bacterin International Holdings, Inc. dated June 19, 2015 entitled “Bacterin Announces signing of agreement with Yankee Alliance” |
Exhibit 99.1
Bacterin International announces signing of agreement with Yankee Alliance
BELGRADE, Mont., June 19, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary biomaterials, today announced the signing of an agreement with Yankee Alliance, a group purchasing organization (GPO) with more than 11,500 members. The agreement covers Bacterin's complete line of biologic implants, including 3Demin cortical fiber allografts. The contract is a three-year agreement extending through June, 2018.
"Yankee Alliance works hard to contract with suppliers who deliver quality products that provide all-around value," said Bob Di Silvio, President of Bacterin. "This new contract will allow Yankee Alliance Members to access Bacterin's entire portfolio of best in class biomaterials. We look forward to growing our relationship with Yankee Alliance."
This is the first GPO to include Bacterin's 3Demin family of allografts. The 3Demin Boats, Strips, and Fibers were developed to compete in the domestic bone replacement market, a $1.7 billion annual business segment (Source: BioMedGPS, LLC), and serve as a complement to our proprietary demineralized bone matrix (DBM) portfolio. Since launching 3Demin in late 2014, Bacterin has experienced positive adoption of this new allograft category and anticipates it will continue to contribute to Bacterin's growth. In addition to this agreement, Yankee Alliance has access to Bacterin's full product portfolio of allografts through their affiliation with Premier, Inc., in which Bacterin serves as a contracted biologics supplier.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (BONE) develops, manufactures and markets biologics products to domestic and international
markets. Bacterin's proprietary methods optimize the growth factors in human allografts to promote bone growth, subchondral repair
and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of
back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral
repair in knee and other joint surgeries.
For further information, please visit www.bacterin.com.
About Yankee Alliance
Yankee Alliance, an owner of Premier
Inc., is a group purchasing organization founded in 1984 on a belief in collaboration, that working together can achieve more than
working alone. Our mission is twofold: to work with members to reduce supply and operating expenses through aggregation of data,
purchasing, ideas and knowledge and to excel in strategic innovations that continually assist members in reducing their cost while
recognizing their individual needs. Today Yankee Alliance remains true to the foundational belief in collaboration and has grown
to over 11,500 members in all classes of trades across all 50 states. For more information visit www.yankeealliance.com.
For more information please contact: Amy Andrade, Vice President, Administration, Yankee Alliance, (978)470-2000 or at aandrade@yankeealliance.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include
statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such
as "continue," "efforts," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," "projects," "forecasts," "strategy," "will,"
"goal," "target," "prospects," "potential," "optimistic," "confident,"
"likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may
be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and
actual results may differ materially depending on a variety of important factors, including, among others: the ability of the Company's
sales force to achieve expected results, the Company's ability to meet its existing and anticipated contractual obligations, including
financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash
flow; the Company's ability to obtain shareholder approval of financing transactions; the Company's ability to develop, market,
sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the
Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes
in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills
and expertise; the Company's ability to successfully conclude government investigations; the impact of changes in market, legal
and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional
risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk
Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Investor Contact:
COCKRELL GROUP
Rich Cockrell
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com